Mechanism
How ibogaine acts on the brain
Ibogaine is a naturally occurring indole alkaloid extracted from the root bark of Tabernanthe iboga, a shrub native to Central Africa used ceremonially in the Bwiti spiritual tradition. Unlike classical psychedelics (psilocybin, LSD), ibogaine operates across a broad receptor profile simultaneously, which accounts for both its unusual therapeutic properties and its cardiovascular risk profile.
Primary receptor targets: NMDA receptor antagonism (comparable mechanism to ketamine, accounting for dissociative properties), kappa-opioid receptor agonism, and inhibition of the dopamine transporter and serotonin transporter. It also has affinity for sigma-1 receptors and voltage-gated sodium channels — the latter contributing to cardiac conduction risk.
Post-acute neuroplasticity: In the 24–72 hours following an ibogaine session, plasma levels of GDNF (glial cell line-derived neurotrophic factor) and BDNF (brain-derived neurotrophic factor) are measurably elevated. This neuroplasticity window is hypothesised to be the substrate for durable anti-craving and mood effects — the brain becomes more plastic, and negative associations (to opioids, alcohol, or traumatic memories) can be processed and revised rather than merely suppressed.
Noribogaine: Ibogaine is rapidly metabolised in the liver to noribogaine, its primary active metabolite. Noribogaine has a half-life of 24–72 hours (compared to ibogaine's 4–7 hours) and is detectable for days to weeks following a single dose. Noribogaine's sustained opioid receptor and serotonin transporter activity is the primary mechanism behind its extended anti-craving effects, which distinguish it from shorter-acting interventions. The acute psychedelic experience lasts 12–30 hours; the neurobiological effects extend considerably longer.
Trial evidence
What the research has measured
The ibogaine evidence base is small by pharmaceutical standards but includes one landmark controlled study with effect sizes rarely seen in psychiatric research. The bulk of human data is observational — conducted outside of conventional clinical settings due to legal constraints in most countries. The Stanford 2024 study is the methodological high-water mark of the field.
| Study / Population | Design & n | Primary outcome | Journal & Year |
|---|---|---|---|
| Cherian KN et al. — TBI veterans Stanford; licensed Mexico clinic |
Controlled study n=30 |
PTSD −88% (PCL-5); depression −87% (PHQ-8); disability −78% (WHODAS) at 1-month follow-up | Nature Medicine, 2024 PMID 38279043 |
| Brown TK, Alper K — opioid use disorder Observational, 12-month follow-up |
Observational n=88 |
~50–60% reduction in opioid use at 12-month follow-up | Am J Drug Alcohol Abuse, 2018 PMID 28662619 |
| Noller GE et al. — opioid dependence 12-month observational |
Observational n=14 |
Sustained reduction in opioid dependence at 12 months | Am J Drug Alcohol Abuse, 2018 PMID 28664772 |
| Koenig X, Hilber K — cardiac safety review Systematic review |
Systematic review | QTc prolongation mechanism; fatality pattern analysis — most deaths in patients with pre-existing cardiac conditions or no monitoring | Molecules, 2015 PMID 25622253 |
| Litjens RP, Brunt TM — toxicology review | Review | Comprehensive toxicology profile; adverse event characterisation | Clin Toxicol, 2016 PMID 26865161 |
| Mexico clinic retrospective cohort Telemetry-monitored facilities |
Retrospective cohort n=191 |
Zero deaths recorded at telemetry-monitored clinics with full cardiac pre-screening | Retrospective cohort data |
The Stanford 2024 study represents some of the largest effect sizes reported for any single-session psychiatric intervention in this population. Read the full clinical guide including Mexico clinic comparison →
Dosage & Protocol
Clinical protocol and pre-treatment requirements
Ibogaine is administered as a single flood dose in a supervised medical setting. The protocol is not self-administerable — it requires continuous cardiac monitoring through the peak effect window and an experienced clinical team. The pre-treatment workup is as important as the treatment itself: patient selection errors are the primary cause of adverse outcomes in the published record.
| Dose | 10–25 mg/kg total alkaloid (flood dose) |
| Pre-treatment screening | 12-lead ECG, cardiac blood panel (electrolytes, liver function), QTc-prolonging medication screen, substance washout period |
| Co-administration | Magnesium glycinate supplementation (reduces QTc prolongation risk) |
| Monitoring | Continuous ECG telemetry through peak effect (first 12–18 hours minimum) |
| Acute duration | 12–30 hours (psychedelic phase); metabolite activity continues 24–72+ hours |
| Setting | Residential medical facility only — never self-administered or administered outside a monitored clinical environment |
Safety & Cardiac Risk
The cardiac risk is real and manageable
Ibogaine has caused fatalities. Cardiac screening is not optional — it is the difference between safe and unsafe treatment. The deaths in the published record share a common pattern: pre-existing cardiac conditions that were not identified, QTc-prolonging medications that were not stopped, or no ECG monitoring during the acute phase. All three are preventable failures of patient selection and clinical protocol.
Primary mechanism of cardiac risk: Ibogaine blocks cardiac hERG potassium channels, which prolongs the QT interval on ECG. Prolonged QTc predisposes to a potentially fatal arrhythmia called Torsades de Pointes (TdP). This risk is dose-dependent, additive with other QTc-prolonging drugs, and dramatically amplified by underlying cardiac structural disease or electrolyte imbalance.
Absolute contraindications:
- QTc interval >500ms at baseline
- Congenital long QT syndrome (LQTS) or family history
- Structural heart disease (cardiomyopathy, valvular disease, prior MI)
- Concurrent QTc-prolonging medications — this category includes tricyclic antidepressants, some SSRIs (citalopram, escitalopram), methadone, certain fluoroquinolone and macrolide antibiotics
- Active psychosis or severe psychiatric comorbidity
- Significant liver disease (impairs ibogaine metabolism)
- Pregnancy
Acute experience: The psychedelic phase is described as intense and frequently confrontational. Patients report vivid visual and auditory phenomena, a review of significant life memories, and a strong somatic component including ataxia and nausea. It is not a comfortable or recreational experience. This intensity is considered part of the therapeutic mechanism — not a side effect to be minimised.
The 191-patient Mexico cohort data is the strongest available evidence that ibogaine can be administered safely when patient selection and monitoring protocols are rigorously followed. Zero deaths in a screened, telemetry-monitored population stands in direct contrast to the adverse event record from unscreened or unmonitored administration contexts.
UK Regulatory Position
Class A in the UK — no legal treatment pathway
In the United Kingdom, ibogaine is a Class A, Schedule 1 controlled substance under the Misuse of Drugs Act 1971. Class A is the highest classification — possession carries a maximum 7-year sentence, supply a maximum of life imprisonment. Schedule 1 means it is classified as having no accepted medical use, with no licensed prescription pathway available to clinicians. There is currently no legal route by which a UK patient can receive ibogaine treatment within the UK.
In Mexico, ibogaine occupies a grey area distinct from controlled substance status. COFEPRIS (the Mexican Federal Commission for the Protection against Sanitary Risk) has not classified ibogaine as a controlled substance, allowing licensed medical facilities to administer it under medical supervision. This is the legal basis on which specialist treatment clinics in Baja California and other states operate.
In the United States, a Trump administration executive order signed in April 2026 directed federal agencies to accelerate research into psychedelic-assisted therapies, including ibogaine, with particular reference to the veteran TBI/PTSD application documented in the Stanford study. This accelerates US research activity but has no effect on the UK regulatory classification.
Travel for treatment: UK residents travelling to Mexico to receive ibogaine treatment at a licensed facility are not committing an offence under UK law by doing so. The act of travelling abroad and receiving lawful medical treatment in another jurisdiction is not criminalised. Patients should ensure they carry documentation from their treating clinic and are clear on re-entry protocols.
Mexico Clinic Comparison
Principal operators — indicative pricing
The following clinics represent the main English-language operations in Mexico offering medically supervised ibogaine treatment. Pricing reflects full treatment packages including pre-treatment screening, accommodation, and post-treatment integration support. Figures are indicative and subject to change — verify directly with each facility.
Beond
$12,500 – $15,000 USD
Luxury residential programme; full cardiac monitoring; integration therapy included.
Ambio Life Sciences
$10,000 – $14,000 USD
Medical-model protocol; psychiatric screening; telemetry monitoring.
Crossroads Treatment Center
$12,000 – $16,000 USD
Addiction-focused; 12-step integration optional; one of the longest-operating facilities.
Pricing indicative only. ProvenLongevity has no commercial relationship with any of the above facilities.
Limitations
What the evidence does not show
- Randomised controlled trial data at scale. The Stanford 2024 study is the methodological peak of the current evidence base — it is not a Phase III RCT. Observational studies cannot exclude confounders including motivation, setting, and self-selection.
- Long-term outcome data beyond 12 months. Most follow-up windows stop at one year. Durability of effect beyond this period is not established by controlled data.
- Evidence across diverse populations. The most rigorous study was specifically in US special-operations veterans with TBI. Generalisability to other populations — including those without TBI history — is an open question.
- Efficacy data for conditions beyond PTSD and opioid dependence. Ibogaine is being explored for alcohol use disorder, treatment-resistant depression, and other indications. These applications currently lack the same level of human evidence.
- Head-to-head comparison with approved treatments. No trial has directly compared ibogaine against EMDR, extended-release naltrexone, buprenorphine, or other standard-of-care interventions.
References
Primary sources
- 1. Cherian KN, Keynan JN, Anker L, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. 2024;30(2):373–381. PMID 38279043
- 2. Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse. 2018;44(1):24–36. PMID 28662619
- 3. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. 2018;44(1):37–46. PMID 28664772
- 4. Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208–2228. PMID 25622253
- 5. Litjens RP, Brunt TM. How toxic is ibogaine? Clinical Toxicology. 2016;54(4):297–302. PMID 26865161